Companies Owned by Patrick Soon-Shiong: Stakes, Investments & Exits

Patrick Soon-Shiong's investment base originated in pharmaceutical businesses built around manufacturing and drug development. APP Pharmaceuticals was sold to Fresenius in 2008, followed by Abraxis BioScience's sale to Celgene in 2010. The latter business commercialized Abraxane, an albumin-bound formulation of paclitaxel. These transactions converted operating-company ownership into capital that could support a wider network of healthcare, technology and media interests rather than ending his involvement in the underlying industries.

NantWorks, founded in 2011, became an organizing platform across health sciences, communications and other technologies. NantHealth developed healthcare information and workflow activities, while ImmunityBio emerged as the principal listed immunotherapy business after the 2021 NantKwest combination. We see the structure as a network of related enterprises and financing relationships. A shared founder and service arrangements can connect them operationally, but each company still has its own securities, liabilities, outside investors and commercial requirements.

The acquisition of the Los Angeles Times and San Diego Union-Tribune in 2018 added a different operating challenge. The California News Group assets were acquired through Nant Capital, and the San Diego publication was later sold. The continuing Los Angeles media business has developed a broader proposition involving studios, virtual production and gaming-related activities. Its economic objective differs from clinical drug development, although both require sustained capital and an ability to convert a long-term strategy into commercial demand.

The 2026 investment activity reinforces the continuing importance of healthcare infrastructure. SHINE Technologies links nuclear technology with medical isotope supply, PDS Biotechnology develops immunotherapy programs, and Multiply Labs and Prolific Machines address manufacturing capabilities. Soon-Shiong's commitments therefore span therapies, information systems and the means of producing complex medicines. These are adjacent capabilities rather than one interchangeable biotechnology investment. The financial outcome depends on clinical, regulatory, manufacturing and customer adoption milestones specific to each business, alongside the separate operating demands of his media holdings.

Soon-Shiong's majority position at ImmunityBio is supported by several vehicles rather than a single direct shareholding. Nant Capital owns a substantial block, Cambridge Equities holds another, and California Capital Equity's beneficial ownership includes securities held through NantWorks-related entities. The April 2026 proxy describes these relationships in detail. Their overlapping attribution means the individual vehicle percentages cannot be added to Soon-Shiong's personal reported percentage as though they represent wholly separate holdings owned by unrelated investors.

The difference between 65.5% beneficial ownership in April and approximately 62.2% outstanding-share ownership in June also requires care. The proxy calculation includes certain shares obtainable through conversion or exercise, while the later risk disclosure refers to shares already outstanding. We treat the measurements as answering different questions rather than assuming they describe a simple three-percentage-point sale. Either disclosure supports a majority position, but the denominator and included securities determine the precise numerical interpretation.

At PDS Biotechnology, the September 2026 financing created minority investor protections and board representation. Nant and its affiliates can designate two directors while maintaining the specified ownership threshold. That is meaningful influence without proof of outright corporate control. SHINE Technologies and Prolific Machines likewise appointed Soon-Shiong to their boards in connection with investment activity. A board position can support collaboration and oversight, but its existence does not make the investor entitled to direct all management decisions or retain all future enterprise value.

Nant Capital's newspaper ownership operates through a different chain from NantHealth's connection with NantWorks. The Los Angeles Times shares a common investor with those scientific enterprises while serving a different customer base and retaining its own operating demands. The common organizing fact is the founder's capital and the actual vehicles through which it is deployed. Distinguishing controlled subsidiaries, overlapping beneficial ownership and negotiated minority rights preserves the economic substance of that network while avoiding a fictional linear ownership structure across the entire portfolio.

SHINE Technologies announced $240 million of equity funding in February 2026, including a $150 million Soon-Shiong investment. The related NantWorks partnership includes priority arrangements for Lu-177 supply, connecting the capital allocation with a medical-isotope strategy. That is a more specific industrial rationale than a generic interest in nuclear fusion. The investment supports an external enterprise and a commercial relationship, while SHINE's total funding and technical ambitions remain distinct from the size or value of his individual stake.

The PDS Biotechnology transaction closed an initial tranche in September 2026, with approximately $11.3 million of gross proceeds for the financing as a whole. Additional funding is linked to a clinical-development milestone, and the structure includes warrants. We distinguish funded capital from conditional commitments because an announced maximum financing amount is not necessarily cash received at the first closing. Nant's board-designation rights also add governance influence to the economic exposure created by the securities purchased.

Multiply Labs' October 2026 Series B raised $75 million from an investor group led by Soon-Shiong with NantWorks. Prolific Machines announced the initial closing of a $50 million Series B2 later that month, co-led by Nant Capital and Atoms & Bits. Both address biomanufacturing, but their technical approaches differ: robotic automation at Multiply Labs and light-based control of cellular processes at Prolific Machines. The round totals describe company fundraising, not a disclosed personal check for the entire amount.

Older outside holdings add different exposures. Directa Plus disclosed Nant Capital and Soon-Shiong with 39.45% of its shares at the end of 2024, while its shareholder page was updated in March 2026. His 4% Los Angeles Lakers position was reaffirmed in August 2026. Neither provides the same operating authority as the ImmunityBio majority. Taken together, the investments range from strategic healthcare collaboration to public materials technology and sports, with each security or contract defining its own rights, liquidity and potential capital calls.

Deal size comparison

Bars share one scale. Only deals with a disclosed value are shown.

APP Pharmaceuticals' sale to Fresenius in 2008 was a major realization from Soon-Shiong's pharmaceutical manufacturing interests. Abraxis BioScience followed with its 2010 sale to Celgene. The Abraxis announcement valued the cash-and-stock consideration at approximately $2.9 billion before additional contingent rights, while later company biographies cite a larger realized transaction value. Those measures describe different components and valuation points. They should not be converted into a single supposedly exact personal payout for the founder.

NantKwest's 2021 merger with the privately held ImmunityBio business is a different kind of former-company event. The separate NantKwest identity was replaced by the combined ImmunityBio structure, with Soon-Shiong retaining a controlling interest. The combination represents a reorganization from our perspective of continuing biotechnology exposure, not a cash exit from cancer immunotherapy. The current listed company carries forward a distinct ownership and operating structure, so counting NantKwest again as an active independent holding would duplicate part of that history.

The San Diego Union-Tribune was acquired alongside the Los Angeles Times in 2018 and sold in July 2023 to MediaNews Group, an Alden Global Capital affiliate. The disposal narrowed the newspaper portfolio while leaving the Los Angeles publication under Soon-Shiong's ownership. The original $500 million package price covered multiple acquired assets and associated obligations; it was not the stand-alone purchase price of each newspaper. The later San Diego sale likewise does not establish the value of the Los Angeles business retained afterward.

Announced plans for broader public participation in the Los Angeles Times Media Group do not constitute a completed exit. A financing plan, a proposed offering and an actual transfer of control are separate events. The same distinction applies to conditional biotech funding commitments, which can expand rather than reduce exposure. Soon-Shiong's realized corporate sales supplied capital for an ongoing cycle of ownership, while mergers and subsidiary disposals changed the form and breadth of that exposure without ending his role as a controlling scientific and media investor.